ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.70
-0.15 (-1.52%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close9.85
Open9.77
Bid9.55 x 2200
Ask9.70 x 800
Day's range9.15 - 9.78
52-week range5.27 - 18.50
Volume6,498,488
Avg. volume4,083,317
Market cap2.176B
Beta (3Y monthly)1.23
PE ratio (TTM)N/A
EPS (TTM)-4.95
Earnings date25 Feb 2019 - 1 Mar 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est16.61
Trade prices are not sourced from all markets
  • Reuters5 days ago

    Family behind Purdue Pharma pushed opioid marketing, Massachusetts says

    Members of the wealthy Sackler family behind Purdue Pharma LP personally pushed the company to boost sales of OxyContin and other opioid products even as questions emerged about the extent its painkillers were being abused, Massachusetts' attorney general alleged on Tuesday. Attorney General Maura Healey filed an amended lawsuit against Purdue and current and former officers and directors of the drugmaker that drew on internal records to reveal new details about family's involvement in the company.

  • Heron Gains on Priority Review Designation for Pain Drug
    Zacks18 days ago

    Heron Gains on Priority Review Designation for Pain Drug

    Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.

  • Options Traders Expect Huge Moves in Endo (ENDP) Stock
    Zacks20 days ago

    Options Traders Expect Huge Moves in Endo (ENDP) Stock

    Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

  • GlobeNewswirelast month

    Catalyst Pharmaceuticals Announces Definitive Agreement with Endo for Vigabatrin Tablets

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has signed a Definitive Agreement with Endo International plc's (ENDP) subsidiary, Endo Ventures Limited, for the further development and commercialization of generic Sabril® (vigabatrin) tablets through Endo’s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical. Pursuant to the agreement, Catalyst will receive an up-front payment,  milestone payments based on achievement of regulatory approvals, and a sharing of defined net profits upon commercialization.

  • Endo International shares fall 8 percent on report of 'shocking' data on opioid distribution
    CNBClast month

    Endo International shares fall 8 percent on report of 'shocking' data on opioid distribution

    Endo International shares slid 8 percent as a '60 Minutes' report on data collected by opioid distributors regarding the amounts and destinations of painkillers is set to air Sunday.

  • Zackslast month

    Generic Drugmakers Down on Allegations of Price Fixing

    An article in The Washington Post levels charges of price fixing against several generic drugmakers, driving their shares down.

  • How Much Upside Do Analysts Expect in Endo Stock?
    Market Realistlast month

    How Much Upside Do Analysts Expect in Endo Stock?

    In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating. The mean rating for Endo International stock is 2.5 with a target price of $17.04, implying an upside potential of 47.3% over Endo International’s closing price of $11.57 on December 7, 2018.

  • What Endo International’s Bottom Line Trend Indicates
    Market Realistlast month

    What Endo International’s Bottom Line Trend Indicates

    How's Endo International Positioned in December? Endo International (ENDP) incurred net interest expenses of $131.85 million in the third quarter of 2018 as compared with $127.52 million in the year-ago period. Endo International’s net loss per share was $0.43 in the third quarter of 2017.

  • How Endo International’s Gross Margin Has Trended
    Market Realistlast month

    How Endo International’s Gross Margin Has Trended

    Endo International’s (ENDP) next two business segments are: The US Generic Pharmaceuticals segment includes solid oral extended release, solid oral immediate release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. Revenues from this segment declined from $294.75 million in the third quarter of 2017 to $257.97 million in the third quarter of 2018. The International Pharmaceuticals segment revenues also declined from $56.43 million in the third quarter of 2017 to $30.25 million in the third quarter of 2018.

  • Understanding Endo International’s Operational Performance
    Market Realistlast month

    Understanding Endo International’s Operational Performance

    How's Endo International Positioned in December? For fiscal 2018 and 2019, Endo is expected to incur research and development expenses of $162.01 million and $165.43 million, respectively. Endo expects its US generic pharmaceuticals research and development costs to decline due to its moving its R&D activities to India.

  • How’s Endo International Positioned in December?
    Market Realistlast month

    How’s Endo International Positioned in December?

    How's Endo International Positioned in December? Endo International (ENDP) is a global specialty pharmaceutical company with a focus on generic and branded pharmaceuticals. Endo International generated total revenues of $745.47 million in the third quarter of 2018 as compared with $786.89 million in the comparable period of 2017.

  • Why Is Endo (ENDP) Down 12.3% Since Last Earnings Report?
    Zackslast month

    Why Is Endo (ENDP) Down 12.3% Since Last Earnings Report?

    Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire2 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Crocs, Ericsson, AAC, Coty, Tutor Perini, and Endo International plc — New Research Emphasizes Economic Growth

    NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • How Is Salix Pharmaceuticals Positioned in November?
    Market Realist2 months ago

    How Is Salix Pharmaceuticals Positioned in November?

    Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017, reflecting ~2% YoY growth. Xifaxan and Relistor primarily contributed to the revenue growth of Salix Pharmaceuticals in the third quarter. In the third quarter, Xifaxan and Relistor witnessed ~11% and 88% YoY organic revenue growth.

  • How Wall Street Analysts View Bausch Health in November
    Market Realist2 months ago

    How Wall Street Analysts View Bausch Health in November

    On November 13, Bausch Health stock closed at $26.63, which is a ~1.60% increase from its prior close of $26.21 on November 12, 2018. On November 13, Bausch Health stock closed at $26.63, a ~92% increase from its 52-week low of $13.86 on November 15, 2017. On October 3, 2018, Bausch Health hit its 52-week high of $28.45.

  • Managers Of This Fund Like The Outlook For Small-Cap Stocks
    Investor's Business Daily2 months ago

    Managers Of This Fund Like The Outlook For Small-Cap Stocks

    This mutual fund is focused on small-cap stocks, and the fund's managers like the outlook for small caps.

  • Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
    Investor's Business Daily2 months ago

    Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

    The best pharmaceutical stocks to buy have a commonality: Strong Composite Ratings and Relative Strength Ratings.

  • Endo International’s Expense Projections for 2018
    Market Realist2 months ago

    Endo International’s Expense Projections for 2018

    On its third-quarter earnings conference call, Endo International (ENDP) raised its projection for operating expenses as a percentage of its total revenue guidance for 2018 from its previously projected range of 26.0%–27.0% to 27.0%.

  • Revenue Projections for Endo International for 2018
    Market Realist2 months ago

    Revenue Projections for Endo International for 2018

    On its third-quarter earnings conference call, Endo International (ENDP) raised its revenue guidance for 2018 from the previously projected range of $2.75 billion–$2.85 billion to $2.87 billion–$2.92 billion mainly due to its stronger-than-anticipated performance YTD (year-to-date).

  • Analysts’ Recommendations for Endo International in November
    Market Realist2 months ago

    Analysts’ Recommendations for Endo International in November

    The stock was trading 22.77% lower than its closing price of $17.08 on November 1. It closed at $13.49 on November 9, 2.27% higher than its previous closing price. Endo International reported its third-quarter earnings results on November 8.

  • BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up
    Zacks2 months ago

    BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up

    BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q3. Sales were almost in line with the consensus mark.

  • Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat
    Zacks2 months ago

    Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat

    Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.

  • Investor's Business Daily2 months ago

    Endo Plans For Cellulite Drug In 2020 — Here's Why Investors Balked

    Endo International stock crashed Thursday despite beating quarterly expectations as the generic drugmaker reportedly plans to launch its cellulite treatment in 2020.

  • Here's Why Endo International Fell as Much as 18.9% Today
    Motley Fool2 months ago

    Here's Why Endo International Fell as Much as 18.9% Today

    The struggling drug company reported third-quarter 2018 operating results.

  • Endo International plc (ENDP) Q3 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Endo International plc (ENDP) Q3 2018 Earnings Conference Call Transcript

    ENDP earnings call for the period ending September 30, 2018.